IL162377A0 - 5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonists - Google Patents
5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonistsInfo
- Publication number
- IL162377A0 IL162377A0 IL16237702A IL16237702A IL162377A0 IL 162377 A0 IL162377 A0 IL 162377A0 IL 16237702 A IL16237702 A IL 16237702A IL 16237702 A IL16237702 A IL 16237702A IL 162377 A0 IL162377 A0 IL 162377A0
- Authority
- IL
- Israel
- Prior art keywords
- diaryl
- pyrazine
- antagonists
- amide derivatives
- amide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0104330A SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Therapeutic agents |
PCT/GB2002/005742 WO2003051851A1 (en) | 2001-12-19 | 2002-12-18 | 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IL162377A0 true IL162377A0 (en) | 2005-11-20 |
Family
ID=20286429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16237702A IL162377A0 (en) | 2001-12-19 | 2002-12-18 | 5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonists |
Country Status (25)
Country | Link |
---|---|
US (1) | US7342019B2 (is) |
EP (1) | EP1458690B1 (is) |
JP (1) | JP2005517655A (is) |
KR (1) | KR20040068286A (is) |
CN (1) | CN1620438A (is) |
AR (1) | AR038044A1 (is) |
AT (1) | ATE354570T1 (is) |
AU (1) | AU2002352425A1 (is) |
BR (1) | BR0214989A (is) |
CA (1) | CA2469786A1 (is) |
CO (1) | CO5590917A2 (is) |
DE (1) | DE60218340T2 (is) |
ES (1) | ES2280599T3 (is) |
HU (1) | HUP0402026A3 (is) |
IL (1) | IL162377A0 (is) |
IS (1) | IS7314A (is) |
MX (1) | MXPA04005990A (is) |
NO (1) | NO20043022L (is) |
NZ (1) | NZ533275A (is) |
PL (1) | PL369731A1 (is) |
RU (1) | RU2004116916A (is) |
SE (1) | SE0104330D0 (is) |
TW (1) | TW200410694A (is) |
WO (1) | WO2003051851A1 (is) |
ZA (1) | ZA200404805B (is) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
GB0216700D0 (en) | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
WO2004029204A2 (en) | 2002-09-27 | 2004-04-08 | Merck & Co., Inc. | Substituted pyrimidines |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
GB0230088D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
GB0302671D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
GB0302673D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
GB0314049D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
US20060135523A1 (en) * | 2003-06-18 | 2006-06-22 | Astrazeneca Ab | 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator |
GB0314057D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314261D0 (en) * | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
WO2005007111A2 (en) | 2003-07-11 | 2005-01-27 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
US7326706B2 (en) * | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
CA2537535A1 (en) * | 2003-09-02 | 2005-03-10 | Solvay Pharmaceuticals Gmbh | Novel medical use of selective cb1-receptor antagonists |
US7320805B2 (en) * | 2003-10-01 | 2008-01-22 | Institut National De La Sante Et De La Recherche Medicale | CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver |
US7517900B2 (en) | 2003-10-10 | 2009-04-14 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
WO2005039579A1 (en) * | 2003-10-24 | 2005-05-06 | Solvay Pharmaceuticals Gmbh | Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors |
AR046132A1 (es) * | 2003-10-24 | 2005-11-23 | Solvay Pharm Gmbh | Composicin farmaceutica que contiene al menos un compuesto con actividad de receptor de cb1, o un profarmaco , tautomero o sal del mismo, como componente activo adecuado para el tratamiento y/o profilaxis de enfermedades relacionadas con el receptor cb1 en pacientes juveniles y/o para el tratamiento |
GB0327331D0 (en) * | 2003-11-25 | 2003-12-31 | Astrazeneca Ab | Therapeutic agents |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
RU2007119315A (ru) | 2004-10-25 | 2008-11-27 | Зольвай Фармасьютиклз Гмбх (De) | Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний |
BRPI0609685A2 (pt) | 2005-04-06 | 2010-04-20 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para tratamento e/ou profilaxia de enfermidades que estão associados com a modulação de receptores de cb1, e utilização dos mesmos |
JP2008536950A (ja) * | 2005-04-18 | 2008-09-11 | ニューロジェン・コーポレーション | 置換ヘテロアリールのcb1拮抗薬 |
WO2007003962A2 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
EP2450350A1 (en) * | 2006-10-04 | 2012-05-09 | F. Hoffmann-La Roche AG | 3-Pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents |
GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
CL2008000017A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
RS52065B (en) | 2007-01-04 | 2012-06-30 | Prosidion Ltd | PIPERIDINSKI GPCR AGONIST |
JP2010514832A (ja) | 2007-01-04 | 2010-05-06 | プロシディオン・リミテッド | ピペリジンgpcrアゴニスト |
AR064735A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
WO2010079241A1 (es) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH458361A (de) | 1965-01-15 | 1968-06-30 | Eprova Ag | Verfahren zur Herstellung von Pyrazincarbonsäuren |
JPS5322529A (en) * | 1976-08-13 | 1978-03-02 | Nippon Soda Co Ltd | Dihydropyrazine derivative and its preparation |
WO1989004308A1 (en) | 1987-11-12 | 1989-05-18 | Terumo Kabushiki Kaisha | Pyrazine derivatives and medicinal preparation containing same |
JPH06501926A (ja) | 1990-08-06 | 1994-03-03 | 藤沢薬品工業株式会社 | 複素環式化合物 |
FR2713225B1 (fr) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
-
2001
- 2001-12-19 SE SE0104330A patent/SE0104330D0/xx unknown
-
2002
- 2002-12-18 PL PL02369731A patent/PL369731A1/xx not_active Application Discontinuation
- 2002-12-18 AU AU2002352425A patent/AU2002352425A1/en not_active Abandoned
- 2002-12-18 NZ NZ533275A patent/NZ533275A/en unknown
- 2002-12-18 HU HU0402026A patent/HUP0402026A3/hu unknown
- 2002-12-18 JP JP2003552736A patent/JP2005517655A/ja active Pending
- 2002-12-18 AT AT02788143T patent/ATE354570T1/de not_active IP Right Cessation
- 2002-12-18 KR KR10-2004-7009589A patent/KR20040068286A/ko not_active Application Discontinuation
- 2002-12-18 IL IL16237702A patent/IL162377A0/xx unknown
- 2002-12-18 CN CNA028281535A patent/CN1620438A/zh active Pending
- 2002-12-18 BR BR0214989-3A patent/BR0214989A/pt not_active IP Right Cessation
- 2002-12-18 MX MXPA04005990A patent/MXPA04005990A/es unknown
- 2002-12-18 RU RU2004116916/04A patent/RU2004116916A/ru not_active Application Discontinuation
- 2002-12-18 DE DE60218340T patent/DE60218340T2/de not_active Expired - Fee Related
- 2002-12-18 US US10/499,054 patent/US7342019B2/en not_active Expired - Fee Related
- 2002-12-18 ES ES02788143T patent/ES2280599T3/es not_active Expired - Lifetime
- 2002-12-18 WO PCT/GB2002/005742 patent/WO2003051851A1/en active IP Right Grant
- 2002-12-18 CA CA002469786A patent/CA2469786A1/en not_active Abandoned
- 2002-12-18 EP EP02788143A patent/EP1458690B1/en not_active Expired - Lifetime
- 2002-12-19 AR ARP020105001A patent/AR038044A1/es not_active Application Discontinuation
- 2002-12-19 TW TW091136671A patent/TW200410694A/zh unknown
-
2004
- 2004-06-16 IS IS7314A patent/IS7314A/is unknown
- 2004-06-17 ZA ZA200404805A patent/ZA200404805B/en unknown
- 2004-07-09 CO CO04065292A patent/CO5590917A2/es not_active Application Discontinuation
- 2004-07-15 NO NO20043022A patent/NO20043022L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2002352425A1 (en) | 2003-06-30 |
CO5590917A2 (es) | 2005-12-30 |
HUP0402026A3 (en) | 2005-08-29 |
HUP0402026A2 (hu) | 2005-02-28 |
EP1458690A1 (en) | 2004-09-22 |
BR0214989A (pt) | 2004-12-14 |
RU2004116916A (ru) | 2005-11-10 |
DE60218340D1 (de) | 2007-04-05 |
PL369731A1 (en) | 2005-05-02 |
ZA200404805B (en) | 2005-08-15 |
KR20040068286A (ko) | 2004-07-30 |
DE60218340T2 (de) | 2007-11-29 |
US20050032808A1 (en) | 2005-02-10 |
ES2280599T3 (es) | 2007-09-16 |
US7342019B2 (en) | 2008-03-11 |
NZ533275A (en) | 2006-02-24 |
SE0104330D0 (sv) | 2001-12-19 |
AR038044A1 (es) | 2004-12-22 |
CN1620438A (zh) | 2005-05-25 |
CA2469786A1 (en) | 2003-06-26 |
EP1458690B1 (en) | 2007-02-21 |
MXPA04005990A (es) | 2004-09-27 |
TW200410694A (en) | 2004-07-01 |
ATE354570T1 (de) | 2007-03-15 |
WO2003051851A1 (en) | 2003-06-26 |
JP2005517655A (ja) | 2005-06-16 |
IS7314A (is) | 2004-06-16 |
NO20043022L (no) | 2004-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL162377A0 (en) | 5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonists | |
IL157704A0 (en) | 4,5-dihydro-1h-pyrazole derivatives having potent cbi-antagonistic activity | |
DK1429761T3 (da) | Hidtil ukendte 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning | |
NO20032892L (no) | 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning | |
SI1555267T1 (sl) | 2,3-DIHIDRO-6-NITROIMIDAZO(2,1-b)OKSAZOLI | |
HK1090368A1 (en) | 2,3,6-trisubstituted-4-pyrimidone derivatives | |
HK1088003A1 (en) | 3-substituted 5,6-diaryl-pyrazine-2-carboxamide and-2-sulfonamide derivatives as cb1 modulators | |
SI1699795T1 (sl) | Substituirani 8-piri(mi)dinil-dihidrospiro-(cikloalkilamin)pirimido(1,2a) pirimidin-6-onski derivati | |
IL160708A0 (en) | 1, 6-naphthyridine derivatives as antidiabetics | |
IL158784A0 (en) | Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives | |
ZA200400926B (en) | Diamine derivatives. | |
IL150550A0 (en) | 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists | |
SI1379522T1 (en) | DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | |
MXPA03006991A (es) | Derivados de piperidina como antagonistas de neurocinina 1. | |
MXPA03008216A (es) | Derivados de 3-fenilo. | |
MXPA03008140A (es) | Amidas de acido benzofuran-2-carboxilico sustituidas. | |
IL162310A0 (en) | 3,4-Dihydro-1h-isoquinoloin-2-yl-derivatives | |
GB0130553D0 (en) | 1,4-Dihydro-1,4-diphenylpyridine derivitives | |
MXPA03008394A (es) | Derivados de biuretano. | |
IL159965A0 (en) | Novel 2,4-diaminothiazole derivatives | |
PL370505A1 (en) | Substituted 1,5-diaminopentan-3-ol compounds | |
PL371851A1 (en) | 3,4-dihydro-1h-isoquinoloin-2-yl-derivatives | |
AU2003255737A8 (en) | Antimicrobial 2, 4-diamino-pteridine derivatives | |
AU2002341261A1 (en) | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists | |
EG23305A (en) | Preparation of 1,2-dicloroethane. |